tetano
Editor, Senior Moderator
PLoS One. 2015 Jun 8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015.
[h=1]The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.[/h] Morokutti-Kurz M[SUP]1[/SUP], K?nig-Schuster M[SUP]1[/SUP], Koller C[SUP]1[/SUP], Graf C[SUP]1[/SUP], Graf P[SUP]1[/SUP], Kirchoff N[SUP]1[/SUP], Reutterer B[SUP]1[/SUP], Seifert JM[SUP]1[/SUP], Unger H[SUP]2[/SUP], Grassauer A[SUP]1[/SUP], Prieschl-Grassauer E[SUP]1[/SUP], Nakowitsch S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Carrageenan is a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections. As infections caused by influenza virus are often accompanied by infections with other respiratory viruses the combination of a specific anti-influenza compound with the broadly active antiviral polymer has huge potential for the treatment of respiratory infections. Thus, the combination of the specific anti-influenza drug Zanamivir together with carrageenan in a formulation suitable for intranasal application was evaluated in-vitro and in-vivo.
[h=4]PRINCIPAL FINDINGS:[/h] We show in-vitro that carrageenan and Zanamivir act synergistically against several influenza A virus strains (H1N1(09)pdm, H3N2, H5N1, H7N7). Moreover, we demonstrate in a lethal influenza model with a low pathogenic H7N7 virus (HA closely related to the avian influenza A(H7N9) virus) and a H1N1(09)pdm influenza virus in C57BL/6 mice that the combined use of both compounds significantly increases survival of infected animals in comparison with both mono-therapies or placebo. Remarkably, this benefit is maintained even when the treatment starts up to 72 hours post infection.
[h=4]CONCLUSION:[/h] A nasal spray containing carrageenan and Zanamivir should therefore be tested for prevention and treatment of uncomplicated influenza in clinical trials.
PMID: 26053018 [PubMed - in process] Free full text
[h=1]The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.[/h] Morokutti-Kurz M[SUP]1[/SUP], K?nig-Schuster M[SUP]1[/SUP], Koller C[SUP]1[/SUP], Graf C[SUP]1[/SUP], Graf P[SUP]1[/SUP], Kirchoff N[SUP]1[/SUP], Reutterer B[SUP]1[/SUP], Seifert JM[SUP]1[/SUP], Unger H[SUP]2[/SUP], Grassauer A[SUP]1[/SUP], Prieschl-Grassauer E[SUP]1[/SUP], Nakowitsch S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Carrageenan is a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections. As infections caused by influenza virus are often accompanied by infections with other respiratory viruses the combination of a specific anti-influenza compound with the broadly active antiviral polymer has huge potential for the treatment of respiratory infections. Thus, the combination of the specific anti-influenza drug Zanamivir together with carrageenan in a formulation suitable for intranasal application was evaluated in-vitro and in-vivo.
[h=4]PRINCIPAL FINDINGS:[/h] We show in-vitro that carrageenan and Zanamivir act synergistically against several influenza A virus strains (H1N1(09)pdm, H3N2, H5N1, H7N7). Moreover, we demonstrate in a lethal influenza model with a low pathogenic H7N7 virus (HA closely related to the avian influenza A(H7N9) virus) and a H1N1(09)pdm influenza virus in C57BL/6 mice that the combined use of both compounds significantly increases survival of infected animals in comparison with both mono-therapies or placebo. Remarkably, this benefit is maintained even when the treatment starts up to 72 hours post infection.
[h=4]CONCLUSION:[/h] A nasal spray containing carrageenan and Zanamivir should therefore be tested for prevention and treatment of uncomplicated influenza in clinical trials.
PMID: 26053018 [PubMed - in process] Free full text